BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 32353564)

  • 1. Synthesis and evaluation of new 1,2,4-oxadiazole based trans- acrylic acid derivatives as potential PPAR-alpha/gamma dual agonist.
    Kaur P; Bhat ZR; Bhat S; Kumar R; Kumar R; Tikoo K; Gupta J; Khurana N; Kaur J; Khatik GL
    Bioorg Chem; 2020 Jul; 100():103867. PubMed ID: 32353564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationships of novel zwitterionic compounds as peroxisome proliferator activated receptor α/γ dual agonists with improved physicochemical properties.
    Shibata Y; Kagechika K; Yamaguchi M; Yoshikawa K; Chiba K; Takano H; Akiyama C; Ono M; Nishi M; Kubo H; Kobayashi Y; Usui H
    Chem Pharm Bull (Tokyo); 2013; 61(12):1248-63. PubMed ID: 24292787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.
    Liu K; Zhao X; Qi X; Hou DL; Li HB; Gu YH; Xu QL
    Eur J Med Chem; 2021 Jun; 218():113388. PubMed ID: 33784603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.
    Ma Y; Wang SQ; Xu WR; Wang RL; Chou KC
    PLoS One; 2012; 7(6):e38546. PubMed ID: 22685582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Structure-Activity Relationships of 2-Aminoacetamide Derivatives as Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists.
    Shibata Y; Kagechika K; Ota M; Yamaguchi M; Setoguchi M; Kubo H; Chiba K; Takano H; Akiyama C; Ono M; Nishi M; Usui H
    Chem Pharm Bull (Tokyo); 2015; 63(8):591-602. PubMed ID: 26235167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
    Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
    Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice.
    Park MH; Park JY; Lee HJ; Kim DH; Park D; Jeong HO; Park CH; Chun P; Moon HR; Chung HY
    PLoS One; 2013; 8(11):e78815. PubMed ID: 24244369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
    Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes.
    Nicholls SJ; Uno K
    Diab Vasc Dis Res; 2012 Apr; 9(2):89-94. PubMed ID: 22407927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining the safety of PPAR agonists - current trends and future prospects.
    Bortolini M; Wright MB; Bopst M; Balas B
    Expert Opin Drug Saf; 2013 Jan; 12(1):65-79. PubMed ID: 23134541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, in silico molecular docking and biological evaluation of novel oxadiazole based thiazolidine-2,4-diones bis-heterocycles as PPAR-γ agonists.
    Nazreen S; Alam MS; Hamid H; Yar MS; Shafi S; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Ali Y; Kharbanda C; Pillai KK
    Eur J Med Chem; 2014 Nov; 87():175-85. PubMed ID: 25255433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics.
    Liu L; Ma Y; Wang RL; Xu WR; Wang SQ; Chou KC
    Drug Des Devel Ther; 2013; 7():279-88. PubMed ID: 23630413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
    Rudolph J; Chen L; Majumdar D; Bullock WH; Burns M; Claus T; Dela Cruz FE; Daly M; Ehrgott FJ; Johnson JS; Livingston JN; Schoenleber RW; Shapiro J; Yang L; Tsutsumi M; Ma X
    J Med Chem; 2007 Mar; 50(5):984-1000. PubMed ID: 17274610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists.
    Zhang H; Ding CZ; Lai Z; Chen SS; Devasthale P; Herpin T; Morton G; Qu F; Ryono D; Smirk R; Wang W; Wu S; Ye XX; Li YX; Apedo A; Farrelly D; Wang T; Gu L; Morgan N; Flynn N; Chu C; Kunselman L; Lippy J; Locke K; O'Malley K; Harrity T; Cap M; Zhang L; Hosagrahara V; Kadiyala P; Xu C; Doweyko AM; Zahler R; Hariharan N; Cheng PT
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1196-205. PubMed ID: 25686852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.